Seroquel Patients May Develop Diabetes
Last Updated on June 26, 2017
Investigation Complete
Attorneys working with ClassAction.org have finished their investigation into this matter.
Check back for any potential updates. The information on this page is for reference only.
Free Consumer Tools:
- Open and Current Class Action Lawsuit Settlements and Rebates
- Open and Current Class Action Lawsuit List, Investigations
- Class Action Lawsuit and Settlement News
- Free Class Action Lawsuit Database
At A Glance
- This Alert Affects
- Millions of people have been prescribed Seroquel since its introduction in 1997, and countless numbers have suffered serious side effects from this defective drug. If you are suffering from the devastating medical problems caused by Seroquel, or if you have lost a loved one to complications from this drug, you should contact a lawyer today for information about your rights.
- Damages
- Seroquel has been found to raise blood sugar while increasing insulin resistance. This may cause the development of diabetes, pancreatitis, diabetic coma, and ketoacidosis.
- Company(ies)
- AstraZeneca
- Additional Details
- Seroquel is a popular antipsychotic drug that works by balancing serotonin and dopamine, two major brain chemicals. It was approved by the Food and Drug Administration (FDA) in 1997.
- Date
- Seroquel has not been the subject of a recall to date.
Marketed by AstraZeneca, Seroquel treats patients with bipolar disorder and schizophrenia. Seroquel balances certain chemicals in the brain to control mood swings associated with bipolar disorder and symptoms of schizophrenia. Unfortunately, many patients taking the drug have developed diabetes.
In Jan. 2004, the FDA advised AstraZeneca to include a warning about high blood sugar and diabetes. The warning also suggested patients beginning treatment with Seroquel undergo blood glucose testing. While some patients who stopped taking Seroquel returned to normal levels of blood sugar, some needed continued anti-diabetic treatment.
In Nov. 2006, the FDA sent AstraZeneca a letter stating the company’s promotional material included allegedly false information. The FDA claims AstraZeneca failed to highlight the risk of diabetes and other risk factors associated with Seroquel.
Before commenting, please review our comment policy.